

**Bilbao (Spain), Press Release, April 06, 2017** – One Way Liver S.L. (OWL Metabolomics), a leader in the field of metabolomics-based testing focused on development of innovative diagnostics for common liver diseases, today announced the company will be participating in the International Liver Congress <sup>TM</sup> 2017, the 52<sup>nd</sup> annual meeting of the European Association for the Study of the Liver (EASL), which takes place in Amsterdam from 19 to 23 of April.

This year's participation includes 3 scientific abstracts and a mini workshop. The abstracts will focus on the elucidation of the mode of action of the fatty acid-bile acid conjugate, Aramchol, in an animal model, which suggests a potential role of this research drug therapy as an anti-fibrotic agent in the landscape of NASH. OWL will also present results of liquid biopsy via metabolomics for NAFLD diagnosis, staging and management, together with NASH subtype identification for application in predictive and personalised medicine.

The workshop program will highlight the use of metabolomics within NASH diagnosis in different aspects like patient selection for clinical trials, diagnosis of patients with type 2 diabetes mellitus and tracking the evolution of NAFLD in obese patients following bariatric surgery, and prediction of patients with a higher likelihood of weight loss.

Specific OWL presentations include:

### 3 Posters:

Abstract SAT-488; Saturday 22 April 2017 | 08:00 - 18:00

Session: Non-invasive assessment of liver disease

**COMPREHENSIVE NAFLD DIAGNOSIS BASED ON A NONINVASIVE  
METABOLOMIC APPROACH IN A LIQUID BIOPSY**

Abstract FRI-358; Friday 21 April 2017 | 08:00 - 18:00

Session: Fatty liver disease: Experimental and pathophysiology

**ARAMCHOL REDUCES ESTABLISHED FIBROSIS IN MCD DIET ANIMAL  
MODEL**

Abstract SAT-330; Saturday 22 April 2017 | 08:00 - 18:00

Session: Fatty liver disease: Experimental and pathophysiology

**NONINVASIVE SERUM BIOMARKERS REFLECT THE EFFECT OF  
ARAMCHOL ON MICE FIBROTIC LIVERS**

### 1 Mini workshop:

Saturday 22 April 2017 | 18:30 - 19:30

**NASH in the spotlight: a metabolomics approach**

### OWL Commercial Exhibit during EASL:

OWL Metabolomics will also be present at the International Liver Congress™ (ILC) with a corporate display in the commercial exhibit space of the **Biotech Village** during ILC.

OWL is pleased to arrange for you a detailed scientific discussion anytime during the Liver Congress. If you or your team are interested in such a meeting, please contact Ms. Miriam Pérez ([mperez@owlmetabolomics.com](mailto:mperez@owlmetabolomics.com)) to arrange for a specific meeting time.

### **About OWL Metabolomics**

OWL Metabolomics is a biotechnology company committed to the identification, validation and global commercialization of novel diagnostic assays for the liver and other prevalent human diseases, including the identification of potential therapeutic targets involved in the development of such diseases. Since its inception in 2002, OWL has pioneered unique diagnostic research within the fatty liver space, a field of considerable focus in new drug development.

The 'OWLiver' and 'OWLiver Care' assays are the world's first metabolomics-based in-vitro tests for diagnosing non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), respectively, using micro-blood samples (<0.3 ml) versus today's diagnostic gold-standard which mandates an invasive liver biopsy.

OWL Metabolomics is a privately-held company based in Derio, Spain. Its main partner is the venture capital management firm Cross Road Biotech Inversiones Biotecnológicas. OWL Metabolomics collaborates globally with hospitals, liver research centers, biotechnology groups and the pharmaceutical industry.

<http://www.owlmetabolomics.com/liver-disease-diagnosis.aspx>

#### **Contact**

One Way Liver, S.L.  
Parque Tecnológico de Bizkaia  
502 Building  
48160 Derio, Spain  
Phone: +34 94 431 85 40